

Special Issue

Tumor Vaccines Frontier Applications in Tumor Microenvironment

Message from the Guest Editors

The tumor microenvironment is the internal environment responsible for the production and existence of tumor cells, including not only the tumor cells themselves, but also various cells such as fibroblasts, immune cells, inflammatory cells, glial cells and other cells around the tumor cells, as well as intercellular stroma, microvascular and biomolecules infiltrated in the nearby area. At present, due to our insufficient understanding of the tumor microenvironment, the development of tumor vaccines is very slow. Therefore, in-depth exploration of the tumor microenvironment is of great value for the development of new tumor vaccines. We welcome the submission of original research and review articles to this Special Issue to gain insight into the molecular mechanisms of the tumor microenvironment in tumorigenesis and development. Potential topics include, but are not limited to, the following:

- Tumor microenvironment and oncology vaccines;
- Cancer immunology and cancer treatment;
- Innate and adaptive immune cells;
- Peptide vaccines and solid tumors;
- Genetically engineered vaccines and tumors;
- Antibody tumor vaccines and tumors.

Guest Editors

Dr. Yutao Wang

Dr. Qiuming Yao

Dr. Yingkun Xu

Dr. Prem Prakash Kushwaha

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/158692

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).